XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
Total
Promissory Notes [Member]
Legacy Series A Preferred Stock [Member]
Legacy Series C-1 Preferred Stock [Member]
Legacy Series C-2 Preferred Stock [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Legacy Series A Preferred Stock [Member]
Preferred Stock [Member]
Legacy Series C-1 Preferred Stock [Member]
Preferred Stock [Member]
Legacy Series C-2 Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Promissory Notes [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Legacy Series A Preferred Stock [Member]
Accumulated Deficit [Member]
Legacy Series C-1 Preferred Stock [Member]
Accumulated Deficit [Member]
Legacy Series C-2 Preferred Stock [Member]
Beginning Balance at Dec. 31, 2022 $ (37,790,539)                 $ 897 $ 4,590,855   $ (42,382,291)      
Beginning Balance (in Shares) at Dec. 31, 2022                   896,580            
Temporary equity accretion of dividends during the period     $ 75,084 $ 18,716 $ 217,368   $ (75,084) $ (18,716) $ (217,368)         $ (75,084) $ (18,716) $ (217,368)
Warrants issued in connection with promissory notes/preferred stock   $ 6,112                   $ 6,112        
Stock-based compensation expense 180,509                   180,509          
Net Income (Loss) (1,828,715)                       (1,828,715)      
Ending Balance at Mar. 31, 2023 (39,743,801)                 $ 897 4,777,476   (44,522,174)      
Ending Balance (in Shares) at Mar. 31, 2023                   896,580            
Beginning Balance at Dec. 31, 2023 24,749,010         $ 1       $ 2,309 83,250,101   (58,503,401)      
Beginning Balance (in Shares) at Dec. 31, 2023           4,243       23,090,585            
Common Stock issued in connection with conversion of Promissory Notes 375,000                 $ 12 374,988          
Common Stock issued in connection with conversion of Promissory Notes (in Shares)                   115,820            
Stock received from AxoBio Disposition (23,456,179)         $ (1)       $ (385) (23,455,793)          
Stock received from AxoBio Disposition (in Shares)           (4,243)       (3,845,337)            
Stock-based compensation expense 211,469                   211,469          
Net Income (Loss) (3,270,959)                       (3,270,959)      
Ending Balance at Mar. 31, 2024 $ (1,391,659)                 $ 1,936 $ 60,380,765   $ (61,774,360)      
Ending Balance (in Shares) at Mar. 31, 2024                   19,361,068